Diagnostics channel feed

Grail’s cancer blood test still isn’t ready for widespread use, experts say

Grail’s can­cer blood test still isn’t ready for wide­spread use, ex­perts say

3 weeks ago

Grail names new CEO as Bob Ragusa retires

Grail names new CEO as Bob Ra­gusa re­tires

3 months ago

The $100 genome, both a scientific milestone and marketing tool, is here

The $100 genome, both a sci­en­tif­ic mile­stone and mar­ket­ing tool, is here

3 months ago

Why did my doctor push Grail’s dubious cancer test?

Why did my doc­tor push Grail’s du­bi­ous can­cer test?

3 months ago

China's MGI sells US subsidiary Complete Genomics after Biosecure Act stalled ambitions

Chi­na's MGI sells US sub­sidiary Com­plete Ge­nomics af­ter Biose­cure Act stalled am­bi­tions

3 months ago

After rallying, Grail's cancer test faces new uncertainty due to UK study

Af­ter ral­ly­ing, Grail's can­cer test faces new un­cer­tain­ty due to UK study

3 months ago

Grail's cancer test shows promise, but misses primary goal in UK study

Grail's can­cer test shows promise, but miss­es pri­ma­ry goal in UK study

3 months ago

Illumina bets on healthcare customers after NIH funding disruptions

Il­lu­mi­na bets on health­care cus­tomers af­ter NIH fund­ing dis­rup­tions

4 months ago

Hims adds Grail's cancer test amid questions about widespread use

Hims adds Grail's can­cer test amid ques­tions about wide­spread use

4 months ago

Exclusive: Cellens raises $6.5M to advance physics-based test for bladder cancer

Ex­clu­sive: Cel­lens rais­es $6.5M to ad­vance physics-based test for blad­der can­cer

5 months ago

Hims launches lab testing for preventive care

Hims launch­es lab test­ing for pre­ven­tive care

7 months ago

Exclusive: Ex-Illumina and Grail employees raise $6.7M to spot liver disease

Ex­clu­sive: Ex-Il­lu­mi­na and Grail em­ploy­ees raise $6.7M to spot liv­er dis­ease

7 months ago

10x Genomics sues DNA giant Illumina over patents

10x Ge­nomics sues DNA gi­ant Il­lu­mi­na over patents

7 months ago

After financial troubles, Grail raises $325M from Hims and others

Af­ter fi­nan­cial trou­bles, Grail rais­es $325M from Hims and oth­ers

7 months ago

Grail reports fewer false alarms for blood cancer test ahead of FDA filing

Grail re­ports few­er false alarms for blood can­cer test ahead of FDA fil­ing

8 months ago

British startup Genomics launches business to help drug developers

British start­up Ge­nomics launch­es busi­ness to help drug de­vel­op­ers

8 months ago

A new use for a very old drug: Aspirin cut risk of recurrence for some types of colorectal cancer in half

A new use for a very old drug: As­pirin cut risk of re­cur­rence for some types of col­orec­tal can­cer in half

9 months ago

A former NIH director reflects on genomic medicine and political 'decapitation'

A for­mer NIH di­rec­tor re­flects on ge­nom­ic med­i­cine and po­lit­i­cal 'de­cap­i­ta­tion'

9 months ago

Labcorp drums up competition for health testing startups

Lab­corp drums up com­pe­ti­tion for health test­ing star­tups

11 months ago

The Trump administration disbanded a newborn screening panel. Advocates now face a harder path

The Trump ad­min­is­tra­tion dis­band­ed a new­born screen­ing pan­el. Ad­vo­cates now face a hard­er path

11 months ago

Aqtual raises $31M to guide rheumatoid arthritis treatments

Aq­tu­al rais­es $31M to guide rheuma­toid arthri­tis treat­ments

11 months ago

Quanterix closes Akoya deal after competing bid

Quan­ter­ix clos­es Akoya deal af­ter com­pet­ing bid

11 months ago

Illumina to buy SomaLogic for $350M upfront, pushing further into proteomics

Il­lu­mi­na to buy So­ma­Log­ic for $350M up­front, push­ing fur­ther in­to pro­teomics

11 months ago

Grail shares jump on study results for cancer test

Grail shares jump on study re­sults for can­cer test

12 months ago